Home ICON Views Emerging Markets Investigators Contact ICON Excellence SERVICES THERAPEUTICS TECHNOLOGY INVESTORS NEWS & EVENTS CAREERS News Events Mediakit Articles & Whitepapers Video Insight Newsletter Awards ICON plc - Clinical Research Organisation (CRO) for Drug Development » News & Events » News » ICON’s Cynthia Dukes Voted one of the Wo... ICON’s Cynthia Dukes Voted one of the World’s Most Influential People in Vaccines Cynthia Dukes is the only CRO representative included in an industry survey by VaccineNatio Dublin, Ireland, 16th September 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Cynthia Dukes, VP, Global Project Management, Vaccines, Infectious Disease, Women’s Health & Primary Care, has been voted one of the 50 Most Influential People in Vaccines following a global industry survey conducted by vaccine industry organisation,VaccineNation. Cynthia was the only CRO representative included in the list. Commenting on the announcement, Dr. Steve Cutler, Chief Operating Officer, ICON plc said: “We are very proud of Cindy’s achievements and are delighted that the vaccine industry recognises her in depth expertise as market-leading within the CRO industry. This latest recognition, coupled with ICON’s Best CRO award at the Vaccine Industry Awards earlier this year, is testament to the innovation our Vaccine Centre of Excellence is delivering to our customers to help them reduce their development costs and speed the delivery of important vaccines to patients worldwide.” In April 2014, ICON was awarded the Best CRO in the Vaccine Industry Excellence Awards which honoured individuals, organisations and initiatives that have made significant contributions to innovation in the field of vaccines. ICON was selected by a panel of global biotechnology industry stakeholders as the best CRO according to the following criteria: Range of services provided in niche and core therapeutic areas. Methods of performance improvement or introduction of new services. Attention to and quality of relationships with clients. Reaching of milestones and final/ongoing outcomes. Building and maintaining existing and long-term partnerships.ICON’s Vaccine Centre of Excellence offers a unique blend of industry expertise with enabling technologies, including Firecrest, ICONIK and ADDPLAN, to help customers identify and overcome the challenges associated with vaccine development. The team is led by Cynthia Dukes who has over 29 years of clinical research experience in vaccines, oncology and infectious disease. To date in ICON, Cynthia has provided strategic and management oversight on numerous pivotal studies leading to the approval of 7 vaccines and 5 oncology therapies. About ICON plc ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 11,000 employees, operating in 38 countries. ICON Media Contact Rebecca Power Weber Shandwick Tel: +44 (0) 207 067 0866 Email: RPower@webershandwick.com This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov. Print page Email to a friend Twitter Facebook Linkedin Disclaimer Privacy Policy Sitemap Cookies